PRODUCT INFORMATION



Edicotinib

Item No. 33347

CAS Registry No.:	1142363-52-7	
Formal Name:	5-cyano-N-[2-(4,4-dimethyl-1-	
	cyclohexen-1-yl)-6-(tetrahydro-	
	2,2,6,6-tetramethyl-2H-pyran-4-yl)-3-	
	pyridinyl]-1H-imidazole-2-carboxamide	
Synonyms:	JNJ-40346527, JNJ-527	\checkmark \downarrow \checkmark \checkmark \land
MF:	C ₂₇ H ₃₅ N ₅ O ₂	
FW:	461.6	
Purity:	≥98%	H
UV/Vis.:	λ _{max} : 225, 249, 292 nm	N O
Supplied as:	A crystalline solid	I
Storage:	-20°C	- _N
Stability:	≥4 years	

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Edicotinib is supplied as a crystalline solid. A stock solution may be made by dissolving the edicotinib in the solvent of choice, which should be purged with an inert gas. Edicotinib is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of edicotinib in ethanol is approximately 20 mg/ml and approximately 30 mg/ml in DMSO and DMF.

Edicotinib is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, edicotinib should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Edicotinib has a solubility of approximately 0.25 mg/ml in a 1:3 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Edicotinib is an inhibitor of colony stimulating factor 1 receptor (CSF1R; IC₅₀ = 3.2 nM).¹ It is selective for CSF1R over KIT and FMS-related tyrosine kinase 3 (FLT3; IC₅₀s = 20 and 190 nM, respectively). Edicotinib (0.1-1,000 nM) reduces CSF1-induced phosphorylation of CSF1R and ERK1/2 in N13 microglia. It reduces spinal motor neuron degeneration and increases the latency to fall in the rotarod test in the P301S mouse model of tauopathy. Edicotinib (15 mg/kg) reduces increases in the colonic weight-to-length ratio, as well as decreases colonic infiltration of macrophages, neutrophils, and CD3⁺ T cells, in an adoptive T cell transfer-induced mouse model of colitis.² It also reduces the viability of L-1236 Hodgkin lymphoma cells with an IC₅₀ value of 264 nM.³

References

- 1. Mancuso, R., Fryatt, G., Cleal, M., et al. CSF1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S mice. Brain 142(10), 3243-3264 (2019).
- 2. Manthey, C.L., Moore, B.A., Chen, Y., et al. The CSF-1-receptor inhibitor, JNJ-40346527 (PRV-6527), reduced inflammatory macrophage recruitment to the intestinal mucosa and suppressed murine T cell mediated colitis. PLoS One 14(11), e0223918 (2019).
- 3. Campion, L., Deangelis, N., Ferrante, C., et al. Abstract B269: Effects of blocking aberrantly expressed CSF-1R in Hodgkin lymphoma. Mol. Cancer Ther. 12(11_Supplement), B269 (2014).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFFTY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

uyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/17/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM